Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome

References

• Center for Disease Control and Prevention. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. Center for Disease Control and Prevention - Morbidity and Mortality Weekly Report (MMWR) Early release 69, March 18, 2020; 2020b.
   Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020a;323(11):1061.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020a;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020e;181(4):894–904.e9.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:10.1002/path.1570.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi:10.1038/s41368-020-0074-x.
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Becavin C, HCA Lung Biological Network, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-6.
   PubMed Web of Science ®Google Scholar
• Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 2020;69(6):1010–1018.
   Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192. doi:10.1007/s11684-020-0754-0.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e278. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134. doi:10.1128/JVI.02232-10.
   PubMed Web of Science ®Google Scholar
• Hirano T, Murakami M. COVID-19: a new virus, but an old cytokine release syndrome. Immunity. 2020;52(5):731–733.
   PubMed Web of Science ®Google Scholar
• Bi Q, Wu Y, Mei S, et al. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. BMJ. 2020;20(8):911–919.
   Google Scholar
• Center for Disease Control and Prevention. Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. Center for Disease Control and Prevention - Morbidity and Mortality Weekly Report (MMWR). 2020a;69(15):477–481.
   PubMed Web of Science ®Google Scholar
• Rodgers GP, Gibbons GH. Obesity and hypertension in the time of COVID-19. JAMA. 2020;324(12):1163.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, the Northwell COVID-19 Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775.
   PubMed Web of Science ®Google Scholar
• Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–19.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002;82(10):1335–1345. doi:10.1097/01.lab.0000032380.82232.67.
   PubMed Web of Science ®Google Scholar
• Okyay R, Sahin A, Aguinada R, Tasdogan A. Why are children less affected by COVID-19? Could there be an overlooked bacterial co-infection? Eurasioan Journal of Medicine and Oncology. 2020;1:104–105.
   Google Scholar
• Yanagi S, Tsubouchi H, Miura A, Matsuo A, Matsumoto N, Nakazato M. The impacts of cellular senescence in elderly pneumonia and in age-related lung diseases that increase the risk of respiratory infections. Int J Mol Sci. 2017;18(3):503.
   PubMed Web of Science ®Google Scholar
• Schouten LR, van Kaam AH, Kohse F, for the MARS consortium, et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Ann Intensive Care. 2019;9(1):55.
   PubMedGoogle Scholar
• Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10(7):514–526. doi:10.1038/nri2802.
   PubMed Web of Science ®Google Scholar
• Cervantes-Barragan L, Zust R, Weber F, et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood. 2007;109(3):1131–1137. doi:10.1182/blood-2006-05-023770.
   PubMed Web of Science ®Google Scholar
• Zust R, Cervantes-Barragan L, Habjan M, et al. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol. 2011;12(2):137–143. doi:10.1038/ni.1979.
   PubMed Web of Science ®Google Scholar
• Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287–1299. doi:10.1084/jem.20180139.
   PubMed Web of Science ®Google Scholar
• Schmitz ML, Kracht M, Saul VV. The intricate interplay between RNA viruses and NF-κB. Biochim Biophys Acta. 2014;1843(11):2754–2764. " doi:10.1016/j.bbamcr.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545. doi:10.1146/annurev-immunol-032713-120231.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.
   PubMed Web of Science ®Google Scholar
• Yang Z, Du J, Chen G, et al. Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL/6 mice. Virol Sin. 2014;29(6):393–402. doi:10.1007/s12250-014-3530-y.
   PubMedGoogle Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):527–331.
   Web of Science ®Google Scholar
• Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, I. China Novel Coronavirus and T. Research, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733., doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Pang IK, Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol Rev. 2012;245(1):209–226. doi:10.1111/j.1600-065X.2011.01073.x.
   PubMedGoogle Scholar
• Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3–S23. doi:10.1016/j.jaci.2009.12.980.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1–3):118–128. doi:10.1007/s12026-014-8534-z.
   PubMed Web of Science ®Google Scholar
• Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301. doi:10.1128/JVI.01281-09.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–9325. doi:10.1128/JVI.01049-10.
   PubMed Web of Science ®Google Scholar
• Koutsakos M, Nguyen THO, Kedzierska K. With a little help from T follicular helper friends: Humoral immunity to influenza vaccination. J Immunol. 2019;202(2):360–367. doi:10.4049/jimmunol.1800986.
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Ran L, Xu L, Canadian SARS Research Network, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81(16):8692–8706. doi:10.1128/JVI.00527-07.
   PubMed Web of Science ®Google Scholar
• Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455. ). "
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol. 2002;14(4):523–536.
   PubMed Web of Science ®Google Scholar
• McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112(15):4719–4724. doi:10.1073/pnas.1502619112.
   PubMed Web of Science ®Google Scholar
• Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7(7):543–555. doi:10.1038/nri2103.
   PubMed Web of Science ®Google Scholar
• Villadangos JA, Heath WR. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin Immunol. 2005;17(4):262–272. doi:10.1016/j.smim.2005.05.015.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–58.
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi:10.1146/annurev-immunol-020711-074950.
   PubMed Web of Science ®Google Scholar
• Jain A, Pasare C. Innate control of adaptive immunity: beyond the three-signal paradigm. J Immunol. 2017;198(10):3791–3800. doi:10.4049/jimmunol.1602000.
   PubMed Web of Science ®Google Scholar
• Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001;2(7):585–589. doi:10.1038/89726.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S127–S132. doi:10.1186/ar567.
   PubMedGoogle Scholar
• Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106(3):255–258.
   PubMed Web of Science ®Google Scholar
• Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17(1):30–48. doi:10.1038/nri.2016.116.
   PubMed Web of Science ®Google Scholar
• Mesel-Lemoine M, Millet J, Vidalain PO, et al. A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes. J Virol. 2012;86(14):7577–7587. doi:10.1128/JVI.00269-12.
   PubMed Web of Science ®Google Scholar
• Pollara G, Kwan A, Newton PJ, Handley ME, Chain BM, Katz DR. Dendritic cells in viral pathogenesis: protective or defective? Int J Exp Pathol. 2005;86(4):187–204. doi:10.1111/j.0959-9673.2005.00440.x.
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–261. doi:10.1146/annurev-virology-110615-042301.
   PubMed Web of Science ®Google Scholar
• Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One. 2012;7(4):e35876. doi:10.1371/journal.pone.0035876.
   PubMed Web of Science ®Google Scholar
• Kovacs A, Ipsen A, Manzel A, Linker R. ACE2 drives dendritic cell function and neuroantigen specific immune responses. Brain Behav Immun. 2013;29:S19–S19.
   Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020c. doi:10.1101/2020.03.14.988345.
   Google Scholar
• Woodhead VE, Binks MH, Chain BM, Katz DR. From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition. Immunology. 1998;94(4):552–559. doi:10.1046/j.1365-2567.1998.00547.x.
   PubMed Web of Science ®Google Scholar
• Marzi A, Gramberg T, Simmons G, et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(21):12090–12095. doi:10.1128/JVI.78.21.12090-12095.2004.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004;78(11):5642–5650. doi:10.1128/JVI.78.11.5642-5650.2004.
   PubMed Web of Science ®Google Scholar
• Chan KY, Xu MS, Ching JC, et al. Association of a single nucleotide polymorphism in the CD209 (DC-SIGN) promoter with SARS severity. Hong Kong Med J. 2010;16(5 Suppl 4):37–42. "
   PubMedGoogle Scholar
• Chan KY, Xu MS, Ching JC, et al. CD209 (DC-SIGN) -336A > G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Hum Immunol. 2010;71(7):702–707. doi:10.1016/j.humimm.2010.03.006.
   PubMed Web of Science ®Google Scholar
• Cai G, Cui X, Zhu X, Zhou J. A Hint on the COVID-19 risk: population disparities in gene expression of three receptors of SARS-CoV. Preprints. 2020. doi:10.20944/preprints202002.0408.v1.
   Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–292.e286. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008;40(1):122–131. doi:10.1016/j.bcmd.2007.06.023.
   PubMed Web of Science ®Google Scholar
• Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. doi:10.1016/j.antiviral.2020.104742.
   PubMed Web of Science ®Google Scholar
• Shiryaev SA, Remacle AG, Ratnikov BI, et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007;282(29):20847–20853. doi:10.1074/jbc.M703847200.
   PubMed Web of Science ®Google Scholar
• Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222(5):734–745. doi:10.1093/infdis/jiaa356.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837. doi:10.1126/science.284.5421.1835.
   PubMed Web of Science ®Google Scholar
• Zhou R, To KK, Wong YC, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020b;53(4):864–877.e5.
   PubMed Web of Science ®Google Scholar
• Cervantes-Barragan L, Kalinke U, Zust R, et al. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009;182(2):1099–1106. doi:10.4049/jimmunol.182.2.1099.
   PubMed Web of Science ®Google Scholar
• Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14 + CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000;30(7):1872–1883. doi:10.1002/1521-4141(200007)30:7<1872::AID-IMMU1872>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood. 2002;100(13):4512–4520. doi:10.1182/blood-2001-11-0097.
   PubMed Web of Science ®Google Scholar
• Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J Immunol. 1994;153(9):4016–4028. "
   PubMed Web of Science ®Google Scholar
• Cong Y, Hart BJ, Gross R, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One. 2018;13(3):e0194868. doi:10.1371/journal.pone.0194868.
   PubMed Web of Science ®Google Scholar
• Scheuplein VA, Seifried J, Malczyk AH, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(7):3859–3869. doi:10.1128/JVI.03607-14.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014;209(9):1331–1342. doi:10.1093/infdis/jit504.
   PubMed Web of Science ®Google Scholar
• Rescigno M, Winzler C, Delia D, Mutini C, Lutz M, Ricciardi-Castagnoli P. Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol. 1997;61(4):415–421.
   PubMed Web of Science ®Google Scholar
• Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014;454-455:197–205. doi:10.1016/j.virol.2014.02.018.
   PubMed Web of Science ®Google Scholar
• Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013;13(9):745–751.
   PubMed Web of Science ®Google Scholar
• Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374. doi:10.1182/blood-2004-10-4166.
   PubMed Web of Science ®Google Scholar
• Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174(12):7977–7985. doi:10.4049/jimmunol.174.12.7977.
   PubMed Web of Science ®Google Scholar
• Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–1147. doi:10.2353/ajpath.2007.061088.
   PubMed Web of Science ®Google Scholar
• Wang WK, Fang CT, Chen HL, Members of the SARS Research Group of National Taiwan University College of Medicine-National Taiwan University Hospital, et al. Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection. J Clin Microbiol. 2005;43(2):962–965. doi:10.1128/JCM.43.2.962-965.2005.
   PubMed Web of Science ®Google Scholar
• Spiegel M, Schneider K, Weber F, Weidmann M, Hufert FT. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol. 2006;87(Pt 7):1953–1960. " doi:10.1099/vir.0.81624-0.
   PubMedGoogle Scholar
• Ziegler T, Matikainen S, RöNkkö E, et al. Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells. JVI. 2005;79(21):13800–13805.
   PubMed Web of Science ®Google Scholar
• Feng Z, Diao B, Wang R, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv Preprint. 2020. doi:10.1101/2020.03.27.20045427.
   Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Hogan RJ, Gao G, Rowe T, et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol. 2004;78(20):11416–11421. doi:10.1128/JVI.78.20.11416-11421.2004.
   PubMed Web of Science ®Google Scholar
• Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–933. doi:10.1086/313792.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy. 2017;15:21 doi:10.1186/s12948-017-0077-0.
   PubMedGoogle Scholar
• Agrawal A, Agrawal S, Gupta S. Role of dendritic cells in inflammation and loss of tolerance in the elderly. Front Immunol. 2017;8:896.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans. Ageing Res Rev. 2011;10(3):336–345. doi:10.1016/j.arr.2010.06.004.
   PubMed Web of Science ®Google Scholar
• Wong CP, Magnusson KR, Ho E. Aging is associated with altered dendritic cells subset distribution and impaired proinflammatory cytokine production. Exp Gerontol. 2010;45(2):163–169. doi:10.1016/j.exger.2009.11.005.
   PubMed Web of Science ®Google Scholar
• Garbe K, Bratke K, Wagner S, Virchow JC, Lommatzsch M. Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age. Hum Immunol. 2012;73(5):493–497. doi:10.1016/j.humimm.2012.02.007.
   PubMed Web of Science ®Google Scholar
• Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. 2009;70(10):777–784. doi:10.1016/j.humimm.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184(5):2518–2527. doi:10.4049/jimmunol.0901022.
   PubMed Web of Science ®Google Scholar
• Qian F, Wang X, Zhang L, et al. Impaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus. J Infect Dis. 2011;203(10):1415–1424. doi:10.1093/infdis/jir048.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol. 2007;178(11):6912–6922. doi:10.4049/jimmunol.178.11.6912.
   PubMed Web of Science ®Google Scholar
• Zacca ER, Crespo MI, Acland RP, et al. Aging impairs the ability of conventional dendritic cells to cross-prime CD8+ T cells upon stimulation with a TLR7 ligand. PLoS One. 2015;10(10):e0140672. doi:10.1371/journal.pone.0140672.
   PubMed Web of Science ®Google Scholar
• Clay CC, Donart N, Fomukong N, et al. Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. Immun Ageing. 2014;11(1):4. doi:10.1186/1742-4933-11-4.
   PubMed Web of Science ®Google Scholar
• Prescott HC, Girard TD. Recovery from severe COVID-19: leveraging the lessons of survival from sepsis. JAMA. 2020;324(8):739.
   PubMed Web of Science ®Google Scholar
• Kumar V. Dendritic cells in sepsis: Potential immunoregulatory cells with therapeutic potential. Mol Immunol. 2018;101:615–626. doi:10.1016/j.molimm.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Wang G, Li X, Zhang L, Elgaili Abdalla A, Teng T, Li Y. Crosstalk between dendritic cells and immune modulatory agents against sepsis. Genes (Basel). 2020b;11(3):323.
   Web of Science ®Google Scholar
• Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol. 2002;168(5):2493–2500. doi:10.4049/jimmunol.168.5.2493.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952–6963. doi:10.4049/jimmunol.166.11.6952.
   PubMed Web of Science ®Google Scholar
• Efron P, Moldawer LL. Sepsis and the dendritic cell. Shock. 2003;20(5):386–401.
   PubMed Web of Science ®Google Scholar
• Tinsley KW, Grayson MH, Swanson PE, et al. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol. 2003;171(2):909–914. doi:10.4049/jimmunol.171.2.909.
   PubMed Web of Science ®Google Scholar
• Ding Y, Chung CS, Newton S, et al. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock. 2004;22(2):137–144. doi:10.1097/01.shk.0000131194.80038.3f.
   PubMed Web of Science ®Google Scholar
• Scumpia PO, McAuliffe PF, O’Malley KA, et al. CD11c + dendritic cells are required for survival in murine polymicrobial sepsis. J Immunol. 2005;175(5):3282–3286.
   PubMed Web of Science ®Google Scholar
• Cao C, Yu M, Chai Y. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death Dis. 2019;10(10):782 doi:10.1038/s41419-019-2015-1.
   PubMedGoogle Scholar
• Bouras M, Asehnoune K, Roquilly A. Contribution of dendritic cell responses to sepsis-induced immunosuppression and to susceptibility to secondary pneumonia. Front Immunol. 2018;9:2590.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Louis S, Pene F, et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med. 2011;37(9):1438–1446.
   PubMed Web of Science ®Google Scholar
• Guisset O, Dilhuydy MS, Thiebaut R, et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 2007;33(1):148–152. doi:10.1007/s00134-006-0436-7.
   PubMed Web of Science ®Google Scholar
• Pastille E, Didovic S, Brauckmann D, et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J Immunol. 2011;186(2):977–986. doi:10.4049/jimmunol.1001147.
   PubMed Web of Science ®Google Scholar
• Poehlmann H, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care. 2009;13(4):R119.
   PubMed Web of Science ®Google Scholar
• Roquilly A, McWilliam HEG, Jacqueline C, et al. Local modulation of antigen-presenting cell development after resolution of pneumonia induces long-term susceptibility to secondary infections. Immunity. 2017;47(1):135–147.e135. doi:10.1016/j.immuni.2017.06.021.
   PubMed Web of Science ®Google Scholar
• Faivre V, Lukaszewicz AC, Alves A, Charron D, Payen D, Haziot A. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS One. 2012;7(10):e47209. doi:10.1371/journal.pone.0047209.
   PubMed Web of Science ®Google Scholar
• Flohé SB, Agrawal H, Schmitz D, et al. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol. 2006;79(3):473–481. doi:10.1189/jlb.0705413.
   PubMed Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732.
   Web of Science ®Google Scholar
• Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020;25(4):668–688.
   PubMed Web of Science ®Google Scholar
• Eastman R, Roth J, Brimacombe R, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683.
   Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797. doi:10.1074/jbc.RA120.013679.
   PubMed Web of Science ®Google Scholar
• Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933 doi:10.1016/j.ijantimicag.2020.105933.
   PubMed Web of Science ®Google Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399–20.
   Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases. Adaptive COVID-19 Treatment Trial (ACTT). 2020. ClinicalTrials.gov Identifier: NCT04280705.
   Google Scholar
• Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786. doi:10.1016/j.antiviral.2020.104786.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020d;30(3):269–271. doi:10.1038/s41422-020-0282-0.
   PubMed Web of Science ®Google Scholar
• Norrie J. Remdesivir for COVID-19: challenges of underpowered studies. The Lancet. 2020;395(10236):1525–1527.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020f;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Thome R, Issayama LK, DiGangi R, et al. Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. Immunol Cell Biol. 2014;92(2):124–132. doi:10.1038/icb.2013.73.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi:10.1038/s41421-020-0156-0.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739.
   Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu J, ZHang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Medrxiv Preprint. 2020. doi:10.1101/2020.03.22.20040758.
   Google Scholar
• Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219.
   PubMedGoogle Scholar
• Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384.
   Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493. doi:10.1001/jama.2020.8630.
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418.
   PubMed Web of Science ®Google Scholar
• Mahevas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
   PubMed Web of Science ®Google Scholar
• Borba MGS, Val FFA, Sampaio VS, CloroCovid-19 Team, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi:10.1001/jamanetworkopen.2020.8857.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:1849.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med. 2020;383(6):517–525.
   PubMed Web of Science ®Google Scholar
• Ornstein MH, Sperber K. The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum. 1996;39(1):157–161. doi:10.1002/art.1780390122.
   PubMedGoogle Scholar
• Ma JP, Xia HJ, Zhang GH, Han JB, Zhang LG, Zheng YT. Inhibitory effects of chloroquine on the activation of plasmacytoid dendritic cells in SIVmac239-infected Chinese rhesus macaques. Cell Mol Immunol. 2012;9(5):410–416. doi:10.1038/cmi.2012.22.
   PubMed Web of Science ®Google Scholar
• Thome R, Bonfanti AP, Rasouli J, et al. Chloroquine-treated dendritic cells require STAT1 signaling for their tolerogenic activity. Eur J Immunol. 2018;48(7):1228–1234. doi:10.1002/eji.201747362.
   PubMed Web of Science ®Google Scholar
• Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Giardino Torchia ML, Ciaglia E, Masci AM, et al. Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One. 2010;5(6):e11052. doi:10.1371/journal.pone.0011052.
   PubMed Web of Science ®Google Scholar
• Gruber A, Wheat JC, Kuhen KL, Looney DJ, Wong-Staal F. Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. J Biol Chem. 2001;276(51):47840–47843. doi:10.1074/jbc.M105582200.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):23. doi:10.1186/s12941-020-00368-w.
   PubMed Web of Science ®Google Scholar
• Ventre E, Rozieres A, Lenief V, et al. Topical ivermectin improves allergic skin inflammation. Allergy. 2017;72(8):1212–1221. doi:10.1111/all.13118.
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. doi:10.1146/annurev-pathol-121808-102144.
   PubMed Web of Science ®Google Scholar
• Sanmarti R, Ruiz-Esquide V, Bastida C, Soy D. Tocilizumab in the treatment of adult rheumatoid arthritis. Immunotherapy. 2018;10(6):447–464. doi:10.2217/imt-2017-0173.
   PubMed Web of Science ®Google Scholar
• Emory University. Tocilizumab for the treatment of cytokine release syndrome in patients with COVID-19 (SARS-CoV-2 Infection). 2020. ClinicalTrials.gov Identifier: NCT04361552.
   Google Scholar
• Hoffmann-La Roche F. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). 2020. ClinicalTrials.gov Identifier: NCT04320615.
   Google Scholar
• Massachusetts General Hospital. Efficacy of tocilizumab on patients with COVID-19. 2020. ClinicalTrials.gov Identifier: NCT04356937.
   Google Scholar
• Memorial Sloan Kettering Cancer Center. Tocilizumab for prevention of respiratory failure in patients with severe COVID-19 infection. 2020. ClinicalTrials.gov Identifier: NCT04377659.
   Google Scholar
• The University of Chicago. Tocilizumab to prevent clinical decompensation in hospitalized, non-critically ill patients with COVID-19 pneumonitis (COVIDOSE). 2020. ClinicalTrials.gov Identifier: NCT04331795.
   Google Scholar
• Meley D, Heraud A, Gouilleux-Gruart V, Ivanes F, Velge-Roussel F. Tocilizumab contributes to the inflammatory status of mature dendritic cells through interleukin-6 receptor subunits modulation. Front Immunol. 2017;8:926. doi:10.3389/fimmu.2017.00926.
   PubMed Web of Science ®Google Scholar
• Mizumoto N, Gao J, Matsushima H, Ogawa Y, Tanaka H, Takashima A. Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood. 2005;106(9):3082–3089. doi:10.1182/blood-2005-03-1161.
   PubMed Web of Science ®Google Scholar
• Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998;161(6):3042–3049.
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28(6):2045–2054.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114(1):135–141. doi:10.1046/j.1523-1747.2000.00833.x.
   PubMed Web of Science ®Google Scholar
• Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol. 2019;10:766.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95. doi:10.1038/cr.2016.157.
   PubMed Web of Science ®Google Scholar
• Ueno K, Kinjo Y, Okubo Y, et al. Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii. Infect Immun. 2015;83(4):1577–1586. doi:10.1128/IAI.02827-14.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Y, Yao Z, Moorman JP, Jia Z. Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology. 2012;136(4):385–396. doi:10.1111/j.1365-2567.2012.03590.x.
   PubMed Web of Science ®Google Scholar
• Aivita Biomedical, Inc. Phase Ib-II trial of dendritic cell vaccine to prevent COVID-19 in adults. 2020. ClinicalTrials.gov Identifier: NCT04386252.
   Google Scholar
• Shenzhen Geno-Immune Medical Institute. Immunity and safety of covid-19 synthetic minigene vaccine. 2020. ClinicalTrials.gov Identifier: NCT04276896.
   Google Scholar
• Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials. Cureus. 2020;12(5):e8342.
   PubMed Web of Science ®Google Scholar
• Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. J Virol. 2002;76(5):2274–2278. doi:10.1128/jvi.76.5.2274-2278.2002.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e1039. doi:10.1016/j.cell.2020.04.026.
   PubMed Web of Science ®Google Scholar